MST1 and cancer: However, our experiments on MCF-7 human breast cancer cells treated with DOX and XMU-MP-1, a novel MST1 pharmacological inhibitor, showed that MST1 inhibition does not only affect DOX cytotoxicity at all, but it reduces the clonogenic potential of cancer cells, also in the absence of DOX treatment.